BioMarin Pharmaceutical

Últimas notícias

Manchetes no idioma original da fonte.

• What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders (abre em uma nova aba)

  Simply Wall Street · 2 de out. de 2026

• After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. (abre em uma nova aba)

  Stock Titan · 1 de out. de 2026

• The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) (abre em uma nova aba)

  Yahoo Finance · 1 de out. de 2026

• BioMarin and Profluent partner on AI-designed enzyme therapies (abre em uma nova aba)

  Pharmaceutical Technology · 1 de out. de 2026

• BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration (abre em uma nova aba)

  Simply Wall Street · 1 de out. de 2026

• BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth (abre em uma nova aba)

  AD HOC NEWS · 30 de set. de 2026

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (abre em uma nova aba)

  TradingView · 30 de set. de 2026

• BioMarin Grants Ascendis Global License, Secures Royalty Revenues (abre em uma nova aba)

  tipranks.com · 30 de set. de 2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (abre em uma nova aba)

  TradingView · 30 de set. de 2026

• BioMarin lays off 117 California workers to consolidate footprint (abre em uma nova aba)

  Fierce Pharma · 30 de set. de 2026

• Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI (abre em uma nova aba)

  marketscreener.com · 30 de set. de 2026

• Profluent Partners With BioMarin to Design Novel Medicines Using AI (abre em uma nova aba)

  Business Wire · 30 de set. de 2026

• Layoff Tracker: Novo, BioMarin, Enanta dole out pink slips (abre em uma nova aba)

  BioSpace · 30 de set. de 2026

• BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board (abre em uma nova aba)

  Simply Wall Street · 26 de set. de 2026

• BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish (abre em uma nova aba)

  AD HOC NEWS · 23 de set. de 2026

• BioMarin Pharmaceutical stock holds near its 52-week low (abre em uma nova aba)

  AD HOC NEWS · 22 de set. de 2026

• BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) (abre em uma nova aba)

  Seeking Alpha · 21 de set. de 2026

• BioMarin Pharmaceutical stock holds near a $12.38 billion value (abre em uma nova aba)

  AD HOC NEWS · 20 de set. de 2026

• What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? (abre em uma nova aba)

  Yahoo Finance · 19 de set. de 2026

• BioMarin stock steadies after September 17 close (abre em uma nova aba)

  AD HOC NEWS · 18 de set. de 2026

• BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone (abre em uma nova aba)

  Yahoo Finance · 18 de set. de 2026

• What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders (abre em uma nova aba)

  Simply Wall Street · 17 de set. de 2026

• BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) (abre em uma nova aba)

  Kalkine Media · 15 de set. de 2026

• BioMarin's stock target raised to $97 after pos... (abre em uma nova aba)

  Pluang · 15 de set. de 2026

• BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts (abre em uma nova aba)

  Fierce Pharma · 15 de set. de 2026

• Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com (abre em uma nova aba)

  Investing.com India · 14 de set. de 2026

• BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (abre em uma nova aba)

  PR Newswire · 14 de set. de 2026

• BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units (abre em uma nova aba)

  Stock Titan · 14 de set. de 2026

• BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board (abre em uma nova aba)

  TradingView · 14 de set. de 2026

• BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board (abre em uma nova aba)

  citybiz.co · 14 de set. de 2026